Skip to main content
. 2024 May 28;42(23):2790–2799. doi: 10.1200/JCO.23.01462

FIG 2.

FIG 2.

TTD in (A) GHS/QoL, (B) physical functioning, and (C) role functioning. HRs were calculated versus sorafenib. GHS, global health status; HR, hazard ratio; QoL, quality of life; STRIDE, Single Tremelimumab Regular Interval Durvalumab; TTD, time to deterioration.